Method of improvement of visual functions at primary open angle glaucoma with normalised intraocular tension

FIELD: medicine.

SUBSTANCE: invention concerns ophthalmology and can be used for improvement of visual functions at primary open angle glaucoma with the normalised intraocular tension. Parabulbar introduction of the 5% Mexidol solution is performed within 10-12 days. In addition nimodipine is administered intravenously in a dose of 10 mg once a day within 10-12 days. Noopept is administered perorally in a dose of 10 mg 2 times a day within 1 month.

EFFECT: method allows strengthening antioxidising activity and circulation in eye tissues, increasing regenerating effect of nervous fibers.

8 tbl, 4 ex

 

The invention relates to medicine, namely to ophthalmology, and can be used in the treatment of progressive primary open-angle glaucoma (POAG) with normalized intraocular pressure.

Despite advances in the diagnosis and treatment of glaucoma in some patients (30%) is the progressive loss of visual functions even when resistant normalization of intraocular pressure (IOP). Glaucomatous optic neuropathy (GON) is the essence of the disease POAG. The pathogenesis of GON includes several factors: biomechanical - deflection grating membrane as a result of increased IOP above the tolerant and the compression of the axonal bundles of the optic nerve in the Lumina microtubule with impaired axonal current; vascular disorders of microcirculation in the area of the optic nerve head (the tendency to vasospasm, rheological disorders, venous stasis, decreased perfusion pressure); metabolic - formation of excess free radicals due to ischemia and increased lipid peroxidation (Moshetova L.K., Alekseev IB, Ivashina A.V. Clinical ophthalmology, Vol.6, 2005, No. 2, p.67-69). Therefore, to achieve success in stabilizing the glaucomatous process normalized IOP by improving blood circulation in the optic nerve head (optic nerve disc), increase the level of metabolism in oporn the x lattice structures of the membrane, and with neuroprotective effects in intact axons.

There is a method of treatment of glaucomatous optic neuropathy (RF patent No. 2308913 from 27.10.2007,), lies in the decompression of the optic nerve is injected into the retro-bulbar space of the implant to reduce the S-shaped bending of the optic nerve at the posterior pole of the eye, which causes an increase in the quality of trophic processes in the optic nerve, the stabilization of the glaucomatous process and improvement of visual functions.

The disadvantage of this method is the need for traumatic surgical procedure incision of the conjunctiva approach to the posterior pole of the eye, as well as mechanical displacement of the optic nerve. In addition, there is the risk of infection of the implant and the tissue of the orbit, the development of retro-bulbar hematoma in the course of this manipulation.

Also known a method of improving visual functions in POAG with normalized intraocular pressure (patent RF №2259203 from 27.03.2005,), consisting of oral administration of lipoic acid simultaneously with beta-carotene in doses of 0.05 g and 10 mg, respectively, 3 times a day for one month. This increases antioxidant activity in the tissues of the eye and, as a consequence, the improvement of visual functions.

However, the disadvantage of this JV is soba is a narrow spectrum of action of these drugs and the absence of pathogenic effects on hemodynamics and neuroprotection cells of the retina (as both drugs belong to the same group of antioxidants), without which it is impossible to adequately improve visual function.

The closest in technical essence is a method of treating patients with optic neuropathy (including glaucoma), which consists in intramuscular or intravenous drip application of antioxidant Mexidol drug 2-4 ml of 5% solution of 1 times a day for 10-12 days (Egorov A., Kasimov AM, Hoop BV the Use of Mexidol in patients with optic neuropathy. Clinical ophthalmology, Vol.3, 2002, No. 2, p.81-83).

The disadvantage of this method is that the effect of the drug through the overall flow, and not directly to the tissues of the eye.

The task of the invention is the stabilization and improvement of visual functions in patients with POAG with normalized intraocular pressure, but deteriorating visual functions by assigning complex treatment of drugs acting on the 3 main pathogenetic link RUT and having angioprotective, neuroprotective and antioxidant properties.

The technical result when using the invention, the increased antioxidant activity and blood flow in the tissues of the eye, increasing the regenerative action of nerve fibers.

This technical result reaches the I way to improve visual function in POAG with normalized intraocular pressure by introducing a 5% solution of Mexidol in 10-12 days, characterized in that Mexidol enter parabulbarno dose of 0.25 mg 1 time per day, additional intravenous nimodipine in the dose of 10 mg 1 time a day for 10-12 days, and oral noopept at a dose of 10 mg 2 times a day for one month.

Mexidol (2-ethyl-6-methyl-3-oxypyridine succinate) - domestic product, is produced in the form of ampoules containing 2 ml of 5% solution (0.1 g of the drug). Registration number 96-432-8. According to the chemical structure of Mexidol is a salt of succinic acid (succinate) and belongs to the group of synthetic antioxidants. Mexidol is an antioxidant, inhibitor of free radicals, membraneelectrode. The drug reduces the activation of lipid peroxidation, increases the physiological activity of the antioxidant system as a whole. He activates energosintezirute mitochondrial function, improves energy volume in the cell. Mexidol has a strong stabilizing effect, exerts a modulating effect on membrane-bound enzymes, ion channels and transporters of neurotransmitters, receptor complexes, including benzodiazepine, GABA and acetylcholine, improves synaptic transmission and, therefore, the relationship of brain structures.

Nimodipine (blocker "slow" Sa2+channels) - registration number UA/3871/01/01 from 09.11.2005, is the unity of the essential substances of this group, possessing and cerebral vasodilating action, improves cerebral circulation and is used for the treatment of acute and chronic vascular pathology of the posterior eye. Additional perfusion is more pronounced in the area damaged and previously under-perfuziruemah blood to parts of the brain.

Noopept (registration No. LS-001577, dated 12.05.2006) according to the chemical structure represents an ethyl ester of N-phenyl-acetyl-L-prolyl-glycine with nootropic activity and shows a marked neuroprotective effect due to the antioxidant properties and antagonistic effect against the neurotoxic effects of excessive glutamate and calcium, characterized by high enzymatic stability, which makes it possible oral use of this drug.

The combined use parabulbar injection drug Mexidol, intravenous infusion of the drug Nimodipine, a tablet form of the drug Noopept on the proposed scheme allows to achieve stabilization of visual functions and to improve visual acuity and visual field in patients with POAG, and to improve hemodynamics and functional status of the retina.

The method of treatment is as follows. Parabulbarno injected 0.5 ml (0.25 mg) of 5% solution of the drug Mexidol 1 time a day for 10-12 is it simultaneously with the first day of treatment using intravenous Nimodipine 50 ml (10 mg), 1 time a day for 10-12 days and oral - protects Noopept (10 mg) 1 tablet 2 times a day for one month.

The proposed method treated 12 patients of the main group with advanced POAG (stages 1-3) and normalized (surgical or medical) intraocular pressure (example 1). The effectiveness of treatment was evaluated according to the Viso - and perimetric studies. Assessment of the functional status of the retina was performed by the method of electroretinography. Assessment of hemodynamic changes in the Central retinal artery was carried out by ultrasonic duplex scanning with color Doppler mapping. Options reducing the deficit area of the Central visual field (CPS) were determined using a computer perimeter. For an objective assessment of the effectiveness of the proposed method 3 was used a control group of patients with advanced POAG (1-3 stages) and normal IOP.

In the first control group (10 persons) conducted monotherapy antioxidant Mexidol drug parabulbarno 0.5 ml (0.25 mg) 5% solution of 1 times a day for 10-12 days (example 2).

In the second control group (9 people) were treated with intravenous drip of angioprotectora Nimodipine 50 ml (0 mg), 1 time a day for 10-12 days (example 3).

In the third control group (8 persons) treatment was performed using the neuroprotector Noopept (10 mg) 1 tablet 2 times a day for one month (example 4).

Assessment of the functional status of the retina, hemodynamic parameters and reduce the deficit area CPS in the control groups were performed similarly to the main group. It should be noted that the distribution of patients in the two groups according to clinical stages were comparable, and the supervision of the treated patients was carried out within 6-8 months.

Example 1. Patient K. 64 years. The diagnosis of Primary open-angle glaucoma II "and" stage right eye. Suffers from glaucoma 3 years. For 2.5 years was compensated IOP medication (ocupress, fotil, xalatan). High IOP (33 mm Hg by pneumotonometry) was reduced with surgery 6 months ago by surgery - deep sclerectomy) and currently is 18 mm Hg, However, visual function continues to deteriorate: visual acuity for the last 3 months decreased from 0.5 to 0.3 with a correction of-0.75 diopters., and total (8 meridians) field of view reduced from 540 to 510 degrees.

The treatment offered by way parabulbarno was administered 0.5 ml (0.25 mg) of 5% solution of the drug Mexidol 1 time a day for 12 days, simultaneously with the first day of treatment was applied intravenously info the AI of the drug Nimodipine 50 ml (10 mg), 1 time a day for 12 days and was carried out by oral administration of the drug Noopept (10 mg) 1 tablet 2 times a day for one month.

These electroretinography and Doppler before and after treatment are presented in tables 1-2.

As a result of the treatment by the proposed method, the total field of vision expanded to 535 degrees. According to a computer perimetric studies the number of cattle in CPS decreased from 48 to 8. The lack of space has decreased by 35%.

Analysis of visual acuity showed improvement after treatment with 0.3 with a correction of-0.75 diopters. to 0.5 with a correction of-1.0 diopters. After 8 months after treatment, the visual acuity and field of vision remained stable.

The above example shows that after treatment was noted a clear improvement in hemodynamics and functional status of the retina, as well as reducing livestock in CPS, which generally resulted in improved visual function and stabilization of the process.

Example 2. Patient L. 62 years Diagnosed with Primary open-angle glaucoma of the left eye II "and" stage. Glaucoma revealed 2 years ago. High intraocular pressure (IOP) reduced by instillation of eye drops Ksalatan 1 time a day 1 drop at night. Currently IOP normalized and is 19 mm Hg (pneumotonometer), but visual function continued to decline (over the last 4 months from 0.6 correction +1,0 diopters. to 0.4 with correction +1,0 diopters). Field of view reduced from 525 to 490 degrees.

Conducted treatment the antioxidant Mexidol drug parabulbarno 0.5 ml (0.25 mg) 5% solution of 1 times a day for 10 days.

These electroretinography and Doppler before and after treatment are presented in tables 3-4.

Analysis of visual acuity showed improvement after treatment with 0.4 correction +1,0 diopters. 0.5 correction +1,0 diopters. Examination of the patient through 7 months: visual acuity decreased to 0.4 with correction +1,0 diopters, and expanding the boundaries of the fields of view were observed.

The above example shows that after treatment was not observed improvements in hemodynamics and functional status of the retina, only the number of cattle in CPS decreased from 43 to 10 and the deficit area decreased by 30%. The expansion of the field of view was observed minor (from 490 to 500 degrees).

Example 3. Patient S. 72 years Diagnosed with Primary open-angle glaucoma of the right eye III "and" stage. Glaucoma identified 2.5 years ago. High intraocular pressure (IOP) reduced by means of surgical intervention (4 months ago surgery - deep sclerectomy) and additional use of eye drops Arutema of 0.5% to 2 times a day. Currently IOP is 17 mm Hg (pneumotonometer), but visual function continued to decline (over the last 4 months with 0.2 correction -1,25 diopters. to 0.08 with correction -1,25 diopters). The total field of view reduced from 360 to 300 degrees.

Treated with angioprotectora Nimodipine intravenous infusion of 50 m is (10 mg), 1 time a day for 12 days.

These electroretinography and Doppler before and after treatment are presented in tables 5-6.

After treatment, the total field of view widened marginally to 320 degrees. According to a computer perimetric studies the number of cattle in CPS decreased from 42 to 40. The lack of space has decreased by 4%.

Analysis of visual acuity showed improvement after treatment with 0.08 correction -1,25 diopters. to 0.1 with correction -1,25 diopters, however, after 6 months, visual acuity decreased to 0,09 with correction -1,25 diopters, and the field of vision narrowed to 310 degrees.

The example shows that directly after treatment, improvement was noted in only the hemodynamics of the eye. Long-term stable stabilization of visual functions have not been reached.

Example 4. The patient Century. 67 years Diagnosed with Primary open-angle glaucoma of the left eye III "and" stage. Suffers from glaucoma 3.5 years. Intraocular pressure (IOP) is compensated by the use of eye drops Betoptic of 0.5% to 2 times a day. Currently IOP is 18 mm Hg, however, visual function continued to decline (over the last 4 months with 0.3 with correction of 1.5 diopters. to 0.1 with correction of 1.5 diopters.). The total field of view reduced from 380 to 310 degrees.

Conducted treatment protects Noopept (10 mg) 1 tab. 2 times a day for one month.

Data ele is triethanolamine and Doppler before and after treatment are presented in tables 7-8.

According to a computer perimetric studies the number of cattle in CPS decreased from 43 to 38. The lack of space fell by 5%.

Analysis of visual acuity showed improvement after treatment with 0.1 correction of 1.5 diopters. to 0.2 with correction of 1.5 diopters. The total field of view remains the same (310 degrees). However, after 8 months, visual acuity was 0.09-0.1 s correction -1,25 diopters, field of vision narrowed to 290 degrees.

The example shows that directly after treatment, improvement was noted in only indicators of the functional status of the retina, and in the remote period marked decline as acuity and field of vision.

In General, in the study group after treatment by the proposed method in 9 patients (75%) showed an improvement of visual functions (visual acuity and visual field) and in 3 (25%) resistant to their stabilization, i.e. the goal was achieved in all patients. For comparison, in the first control group, where monotherapy conducted parabulbar injections antioxidant Mexidol drug, improvement of visual functions was observed in 4 patients (40%) and in 2 (20%) of their stabilization, i.e. the positive effect was achieved only 60% of cases. The second control group, where the treatment was performed by intravenous infusion of angioprotectora Nimodipin, a positive effect was achieved in 4.4% of cases (3 patients showed an improvement of visual functions - 33.3% 1 (11,1%) - their stabilization). 3 the control group, where the treatment was performed using the neuroprotector Noopept oral, a positive effect was achieved only 25% of cases (in 1 patient (12.5 percent) showed improvement of visual functions and in 1 patient (12.5%) of their stabilization).

Thus, the stabilization and improvement of visual functions in progressive primary open-angle glaucoma with normalized intraocular pressure of the proposed method achieved significantly more effective than monotherapy with the use of each drug separately. The proposed method of treatment improves the condition of antioxidant activity, blood circulation in the eye tissues, strengthen regenerating nerve fibers, which leads to the stabilization and improvement of visual functions in patients with advanced primary open-angle glaucoma and normal intraocular pressure.

8,0
Table 1
The impact of treatment on indicators of electroretinography patient K. (example 1)
IndexNormaBefore the treatmentAfter treatment
right eyeright eye
Wave "A"30-60 µv28,749,4
Wave "B"225-400 µv220,4269,2
Table 2
The impact of treatment on the parameters of blood flow in the Central retinal artery, the patient K.
IndicatorsRight eye
Before the treatmentAfter the treatment
Vsyst., cm/c7,79,1
Vdiast., cm/c1,32,8
The Vm., cm/s3,4a 4.9
RI 0,830,69
Table 3
The impact of treatment on indicators of electroretinography patient L (example 2)
IndexNormaBefore the treatmentAfter the treatment
left eyeleft eye
Wave "A"30-60 µv29,129,4
Wave "B"225-400 µv230,4231,2
Table 4
The impact of treatment on the parameters of blood flow in the Central retinal artery of the patient L.
IndicatorsLeft eye
Before the treatmentAfter the treatment
Vsyst., cm/c8,1
Vdiast., cm/c1,41,4
The Vm., cm/s3,63,7
RI0,820,82

Table 5
The impact of treatment on indicators of electroretinography patient C. (example 3)
IndexNormaBefore the treatmentAfter the treatment
right eyeright eye
Wave "A"30-60 µv29,229,3
Wave "B"225-400 µvto 220.1,220,2
the figure 6
The impact of treatment on the parameters of blood flow in the Central retinal artery of the patient C.
Indicatorsright eye
Before the treatmentAfter the treatment
Vsyst., cm/c7,08,3
Vdiast., cm/c1,42,1
The Vm., cm/s3,14,5
RI0,800,75
Table 7
The impact of treatment on indicators of electroretinography patient C. (example 4)
IndexNormaBefore the treatmentAfter the treatment
left eyeleft eye
Wave "A"30-60 µv26,237,6
Wave "B"225-400 µv215,1231,2
Table 8
The impact of treatment on the parameters of blood flow in the Central retinal artery of the patient Century.
IndicatorsLeft eye
Before the treatmentAfter the treatment
Vsyst., cm/c7,07,0
Vdiast., cm/c1,21,3
The Vm., cm/s2,93,0
RI0,830,83

Method for improving visual function in primary open-angle glaucoma with normalized intraocular pressure by introducing 5%is astora of Mexidol in 10-12 days, characterized in that Mexidol enter parabulbarno dose of 0.25 mg 1 time per day, additional intravenous nimodipine in the dose of 10 mg 1 time a day for 10-12 days, and oral noopept at a dose of 10 mg 2 times a day for one month.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention concerns medicine, namely to ophthalmology. It is offered to use a composition containing, at least one agonist BMP-4 for treatment of glaucoma. Thus administer the composition with immediate delivery into an eye of the patient, for example using local eye drops; an oculentum; devices of the slowed down release implanted into a cul-de-sac of an eye either about a sclera of an eye or in an eye; by means of an injection. Concentration of BMP-4 in the composition preferably makes from 0.01 to 2%. The method is based on property of BMP-4 to reduce an ophthalmotonus.

EFFECT: creation of a composition for glaucoma treatment.

8 cl, 15 dwg, 2 tbl, 1 ex

FIELD: medicine; ophthalmology.

SUBSTANCE: cytostatic agent is subconjuctive introduced. Agent introduced is added with 0.08% trypan blue solution in amount 0.05 ml. Introduced agent localisation is visualised. In case agent becomes localized in anterior chamber or escapes through conjunctive suture introduction is stopped. In case agent spreads under conjunctiva dose in required amount is introduced.

EFFECT: lower rate of complications caused by cytostatics introduction.

2 ex

FIELD: medicine; ophthalmology.

SUBSTANCE: carbonic anhydrase inhibitor is instilled. One day after medicamentous therapy started. Azopt therapy is combined with vasotonic massage of anterior ciliary arteries (ACA) that is transconjunctiva ACA effect using multiple alternation of their mechanical compression and decompression by vasotonometer.

EFFECT: higher efficiency of treatment of primary open-angle glaucoma and blood flow improvement of eye great vessel.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: Invention relates to ophthalmology, and can be used for treatment of glaucoma optic neuropathy. Dibicor in dose 0.5g two times a day during 1 month, then cortexin and retinalamin in dose 10 mg intramuscular every second day during 20 days are prescribed. Method allows to increase electrophysiological activity of visual analyser in patients with primary open-angular glaucoma due to pathogenically grounded successive application of said medications, on the first stage of treatment intracellular exchange in ganglionar cells of retina improves, then synaptic lesions and transmission of nerve impulse from retina to cortical centre of visual analyser are activated.

EFFECT: increase of electrophysiological activity of visual analyser in patients with primary open-angular glaucoma.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: method involves introducing anecortavi acetas at a dose of 3-15 mg in posterior juxtascleral injection or injection into vitreous body or as implant.

EFFECT: enhanced effectiveness of treatment.

18 cl, 5 dwg, 4 tbl

FIELD: organic chemistry, medicine, biochemistry pharmacy.

SUBSTANCE: invention relates to using the known 2-phenyl-substituted imidazotriazinone of the formula (I): (vardenafil) possessing improved properties as compared with other known inhibitors of phosphodiesterase-5 (PDE-5), such as sildenafil and tadalafil. Proposed compound is used for preparing drugs used in treatment of cardiac insufficiency.

EFFECT: valuable medicinal and biochemical properties of compound.

1 tbl

FIELD: medicine, ophthalmology, chemical-pharmaceutical industry, pharmacy.

SUBSTANCE: invention relates to design of ophthalmological agents of broad spectrum based on vegetable components, vitamins and trace elements. Agent for treatment of eye diseases comprises bilberry berries of sublimation drying, dihydroquercetin, beta-carotene, selexen, lutein, vitamins B1, B2, B6, B12 and zinc. Agent shows the effect of broad spectrum and possesses regenerating, tonic and regenerative effect being without irritating, allergizing, inflammatory and other undesirable effects, and excluding mechanical contact with eye surface.

EFFECT: valuable medicinal properties of agent.

5 cl

FIELD: medicine.

SUBSTANCE: method involves carrying out tonometry, patient examination in slit lamp light, determining filtration cushion size and relief, carrying out test with sterile air introduced under conjunctiva in operation zone in combination with glycocorticosteroid preparation. Filtration cushion height increasing and air entering the anterior chamber, diuretic drugs are prescribed and preparations inhibiting intraocular fluid secretion. Filtration cushion becoming flat, glycocorticosteroid preparations, enzyme preparations are introduced and antimetabolite is introduced under conjunctiva outside of operation field. Filtration cushion relief being variable and air passes into the anterior chamber, anti-inflammatory therapy, anti-proliferative treatment course, glycocorticosteroid and enzyme preparations are prescribed. Filtration cushion becoming flat, and air does not enter the anterior chamber, gonioscopy is carried out and surgical intervention zones are revised in the cases of open internal fistula and antibiotic of cytostatic activity is to be prescribed. Internal fistula being blocked, laser surgical intervention is carried out. Hypertension being persistent, anti-glaucoma intervention is carried out in another eyeball segment with antibiotic of cytostatic activity being applied.

EFFECT: enhanced effectiveness of treatment selection.

FIELD: organic chemistry, medicine, ophthalmology, pharmacy.

SUBSTANCE: invention relates to novel derivatives of benzo[g]quinoline of the formula (I): as a free base or acid-additive salt used in treatment of glaucoma and myopia, and to a method for their synthesis and a pharmaceutical composition. In compound of the formula (I) each A and B means hydrogen atom (H); X means -CH2; Y means sulfur atom (S); R1 means H or (C1-C4)-alkyl wherein this compound can be in form of a free base or acid-additive salt. Method for synthesis of compound of the formula (I) by claim 1 or its salt involves the conversion step of alkoxy-group in compound of the formula (II): wherein A, B, X, Y and R1 have values given in claim 1; R3 means (C1-C4)-alkyl to hydroxy-group, and conversion of synthesized compounds of the formula (I) to free base or its acid-additive salt.

EFFECT: improved method of synthesis, valuable medicinal properties of compounds and pharmaceutical composition.

7 cl, 1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves administration of chitosan sponge with square up to 2 cm2 into sub-Tenon's space wherein chitosan sponge shows the deacetylation degree 98%, its molecular mass is 1000 kDa and it comprises 2.8 x 10-9 g of hyaluronic acid, 27.8 x 10-8 g of chondroitinsulfuric acid, 3.06 x 10-11 g of cattle serum growth factor and 7 x 10-9 g of heparin per 1 mm2 of chitosan sponge. Method provides stabilizing visual function, to improving vision and expanding vision field based on enhancing sensitivity of optic nerve as result of blood stream enhancing. Invention can be used in treatment of progressing glaucoma with non-stabilizing functions.

EFFECT: improved method of treatment.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to application of peptides of antagonistic action in the relation bradykinin, suitable for medical products for prevention and treatment of diseases influenced by increased activity of matrix metalloproteinase. They are degenerative arthropathies, e.g., osteoarthrosis, spondylosis, as well as cartilage atrophy caused by joit injury or prolonged joint immovability following meniscus or patella damage or ligamentous rupture.

EFFECT: invention provides more effective brake of matrix splitting in comparison with only MMP inhibition of already released or formed tissues.

3 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: 2 blood samples are taken with interval 3 days against complex medicinal supplement under the following scheme. Therapy of the first exfusion day is characterized with single introduction of phetabolyl 0.4 mg/kg intramuscularly, 5% vitamin B1 - 50 mg intravenously, vitamin B12 - 500γ st. units intramuscularly, 5%vitamin C - 150 mg intravenously and 10 % aminoplasmal E - 250 ml intravenously drop-by-drop. The same day and the next two days imply intramuscular injection of ferrum lek 100 mg once, sorbypher 325 mg twice a day, folic acid - 5 mg 3 times a day. For the second day exfusion is accompanying with single subcutaneous introduction of epocryne in dosage 4 thausand UNITS. Then for the third day control inspection is carried out. The second day of exfusion implies single introduction of 5% vitamin B6 - 50 mg intravenously, 5% vitamin C - 150 mg intravenously, vitamin B12 - 500γ st.units intramuscularly and 10% aminoplasmal E - 250 ml intravenously drop-by-drop. This day and in the subsequent two - three days imply intramuscular introduction of ferrum lek 100 mg once, sorbypher 325 mg twice a day, folic acid - 5 mg 3 times a day. For the second day exfusion is accompanying with single subcutaneous introduction of epocryne in dosage 4 thausand UNITS. Then for the third day control inspection is carried out again. Since the first exfusion and before autoblood preparation nutritive supplement is carried out using module protein added to mix "Berlamine Modular" 50 g twice a day daily. After exfusion autoblood is divided on erythrocyte mass and fresh frozen plasma.

EFFECT: prevention of dangerous erythropoiesis and metabolic disorders.

1 ex, 3 cl

FIELD: biotechnology.

SUBSTANCE: disclosed are peptides derived from proenzyme forms of matrix proteinases which represent inhibitors of matrix proteinases. Amino acid sequence is disclosed in description. Described are composition for stimulation of healthy skin formation, containing therapeutically effective amount of peptides. Also disclosed are dressing for wounds, method for stimulation of healthy skin formation and wound healing. Disclosed is using of composition in production of drug for wound healing.

EFFECT: new anti-aging and wound-healing agents.

15 cl, 28 dwg, 6 tbl, 7 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention proposes a pharmaceutical composition used in treatment of patients suffering from cerebrospinal sclerosis. The composition comprises as an active component inhibitor of dipeptidyl peptidase IV (DPIV) of the general formula (I): wherein A means a residue of amino acid comprising at least one functional group in by-side chain; B means oligopeptide comprising up to 20 amino acids in its chain length, or polyethylene glycol of molecular mass up to 20000 g/mole, or optionally substituted organic amine, amide, alcohol, acid or aromatic compound comprising from 8 to 50 carbon atoms representing substituted or optionally substituted phenyl, benzyl, naphthyl, biphenyl and wherein a substitute can mean replacing with one or some groups of alkyl, alkenyl, alkynyl, mono- or multivalent acyl, alkanoyl, alkoxyalkanoyl or alkoxyalkyl as by-side groups; C means group of thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine bound by amide bond with the group A. In animal model study administration of inhibitor DPIV as isoleucylthiazolidine fumarate in the dose 1 mg/kg resulted to the absence of clinical symptoms of disease. In other experiments this inhibitor caused accelerating recovery and shoed anti-inflammatory effect also.

EFFECT: valuable medicinal and biochemical properties of inhibitors.

4 cl, 8 dwg, 14 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with applying a composition that contains antagonists of integrin αvβ3 and/or αvβ5 receptors for manufacturing the medicinal preparation indicated for treating angioproliferative ocular diseases. The compositions mentioned could be presented as nanoparticles. Application of the declared compositions provides the chance for intravitreous introduction.

EFFECT: higher efficiency of therapy.

46 cl, 1 ex, 1 tbl

FIELD: medicine, pharmaceuticals.

SUBSTANCE: disclosed is application of dipeptidyl peptidase inhibitors (DPIV-inhibitors) particularly isoleucyl-tiazolidine as active ingredient of pharmaceutical hypotensive composition for mammalian suffering from diabetes. Disclosed is stabilizing of systolic blood pressure in diabetic fats and lowering levels thereof from 170 mmHg (control animals without isoleucyl-tiazolidine) to 150 mmHg.

EFFECT: new dipeptidyl peptidase inhibitors useful in pharmaceutical hypotensive composition.

9 cl, 9 dwg, 11 tbl, 20 ex

FIELD: biotechnology, medicine, oncology.

SUBSTANCE: invention proposes peptide of the structure Tyr-Ser-Leu and a pharmaceutical composition based on thereof that is used for stimulating antitumor immune response. Also, invention proposes methods for treatment of mammal and for modulation of the immune response. Proposed inventions expand assortment of agents used in treatment of cancer diseases.

EFFECT: valuable medicinal properties of peptide and pharmaceutical composition.

20 cl, 48 tbl

FIELD: chemistry of peptides, medicine, pharmacology.

SUBSTANCE: invention relates to using the combination of bioactive regions SYSMEHFRWGKPV and YGGFM in pro-opiomelanocortine in manufacturing a medicine used in treatment of inflammatory, degenerative and autoimmune diseases, traumas, infections and burns. Also, invention relates to using polypeptide chosen from group: YGGFMSYSMEHFRWGKPVYGGEM, YGGFMSYSMEHFRWGKPV, SYSMEHFRWGKPVYGGFM and compositions eliciting cytoprotective properties. Invention provides enhancing in peptides effect.

EFFECT: valuable medicinal properties of peptides.

9 cl, 1 tbl, 1 dwg

FIELD: medicine, gynecology.

SUBSTANCE: before operation it is necessary to sample patient's blood to divide it into plasma and blood cells. Blood plasma should be divided into three parts and frozen. After operation one should intravenously reinfuse by drops erythrocytic mass incubated for 30 min at 37° C with 2 g lendacyn followed by further lendacyn injection per 1g intramuscularly during the next 6 d. Blood plasma should be portionally defrosted, incubated at 37° C with: 10000 U trasilol, 0.15 g lisozyme, 0.02 g novocain, after incubation it is necessary to add 100 ml gelatinol to be reinfused for a patient on the 2nd, 4th and 6th d against the onset of therapy course through microirrigator withdrawn out of posterior arch during operation. The innovation provides combined impact of antibiotics upon pathological focus biotransformed with erythrocytic mass and local immunomodulating and resolving effect and, thus, decreased formation of adhesions, fistulas and cicatrices.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: virology.

SUBSTANCE: invention proposes different compositions able to induce production of antibodies against Tat HIV-1 that can inhibit multiplication of HIV-1. Also, invention proposes a method for induction of antibodies raised against Tat HIV-1, in vitro method for assay of the presence of antibodies and their titer values, a method for reducing HIV-1 virus levels, sequence of synthetic nucleic acid and synthetic molecule. Proposed group of inventions can be used for inhibition of multiplication of HIV-1 in infected patients and for attenuation of HIV-1 multiplication after the primary infection in early infected persons.

EFFECT: valuable methods and compositions.

39 cl, 7 dwg, 9 tbl, 5 ex

FIELD: medicine.

SUBSTANCE: correction of lipid composition of thrombocyte membranes in patients suffering from metabolic syndrome (MS) is enabled with three-month individually prescribed hypo-calorie diet, graduated physical activity and preparations Pioglitazone dosed 30 mg once a day, Irbesartan dosed 150 mg once a day and Lerkanidipine dosed 10 mg in the morning.

EFFECT: normalisation of lipid composition of thrombocyte membranes in patients suffering from metabolic syndrome and ensured functioning level specific for healthy people resulted from three-month treatment.

1 ex

Up!